

6-11-2020

## Superior Short-Term Patency of Stents Over Balloons in Infrapopliteal Artery Disease

Supraja Thunuguntla

*The University of Texas, Rio Grande Valley*, [supraja.thunuguntla@utrgv.edu](mailto:supraja.thunuguntla@utrgv.edu)

Obinna Echeruo

*The University of Texas Rio Grande Valley*

Charles Mild

*The University of Texas Rio Grande Valley*

Follow this and additional works at: [https://scholarworks.utrgv.edu/som\\_pub](https://scholarworks.utrgv.edu/som_pub)



Part of the [Medicine and Health Sciences Commons](#)

---

### Recommended Citation

Thunuguntla, Supraja; Echeruo, Obinna; and Mild, Charles, "Superior Short-Term Patency of Stents Over Balloons in Infrapopliteal Artery Disease" (2020). *School of Medicine Publications and Presentations*. 81. [https://scholarworks.utrgv.edu/som\\_pub/81](https://scholarworks.utrgv.edu/som_pub/81)

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [justin.white@utrgv.edu](mailto:justin.white@utrgv.edu), [william.flores01@utrgv.edu](mailto:william.flores01@utrgv.edu).

# **Superior Short-Term Patency of Stents Over Balloons in Infrapopliteal Artery Disease**

Supraja Thunuguntla, Obinna Echeruo, Charles Mild

*Internal Medicine Residency Department, The University of Texas Rio Grande Valley*

## **Purpose**

The optimal strategy for revascularization in below-the-knee (BTK) chronic limb-threatening ischemia (CLTI) remains debatable. High restenosis rates of percutaneous transluminal angioplasty (PTA) often warrants re-intervention or amputations. Novel devices such as drug-eluting (paclitaxel) balloons (DEB), stents, and atherectomy devices- directional (HawkOne, SilverHawk, TurboHawk)™ or orbital (DiamondBack 360)™ are used infrequently as therapy when BTK. We aim to compare the rate of total re-occlusion between these interventions.

## **Material & Methods**

A retrospective chart review of 97 patients who underwent BTK percutaneous intervention in 2015-2020 at our hospital. Descriptive statistics were used to assess the distribution of variables; continuous variables (time to readmissions) were summarized as mean values with standard deviations, and categorical variables were summarized as counts and percentages.

## **Results**

Out of the 97 patients, 73.4% met documented Rutherford category V-VI on initial admission, 53.6% patients were readmitted to our facility with Rutherford category IV-VI at 8 +/- 8 months from initial intervention, 79.7% were diabetic and 62.5% were hypertensive. Interventions performed on the 208 arteries were plain balloon angioplasty 57.7%, DEB 2.9%, atherectomy with adjunctive PTA (A+PTA) 28.8%, stent 8.7% and atherectomy with adjunctive stent (A+S) 2.9%. Of the stents placed, 13 were bare-metal stent (BMS) and 11 drug-eluting (everolimus) stent (DES).

Within 12 months from initial intervention, total re-occlusion post PTA occurred at 4 (+/-3) months, A+PTA 3.7 (+/-2) months, and stents 8 (+/-3) months ( $p= 0.015$ ,  $F= 4.6$ ). Comparing stents, restenosis was 53.8% in BMS versus 18.2% in DES ( $p= 0.09$ ) at 6 (+/-3) months readmission. Re-occlusion rates 30 months from initial intervention were 58.1% for uncoated balloons, 33.3% A+PTA, 60% DEB, 50% stents and 50% A+S ( $p= 0.27$ ). 22 patients were not readmitted again for any reason. Of the 17 patients who underwent major amputation (below or above the knee), 10 had triple-vessel involvement below the knee, 4 had osteomyelitis. Restoring straight-line flow in angioplasty was unsuccessful in 10 cases.

## **Conclusion**

These preliminary data suggest superior short term (< 1-year) patency of stents over PTA and A+PTA, BTK. Re-occlusion in A+PTA may be lower than PTA alone. DES seems to have better patency than BMS. Further studies needed to compare clinical outcomes.